 
 
A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and 
Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in 
Patients with Fuchs Endothelial Corneal Dystrophy  
[STUDY_ID_REMOVED] 
Clinical Study Protocol Ver.: 1.0 Document Date: [ADDRESS_1269560] 2019 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269561] read and understood all sections of the protocol entitled “A double-masked, 
randomised, placebo-controlled, parallel- group, 12-week, Phase 2 study to investigate the 
safety and efficacy of ripasudil (K -321) eye drops after descemetorhexis in patient s with 
Fuchs endothelial corneal dystrophy” and the accompanying investigator’s brochure. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Protocol Version 1.0, dated [ADDRESS_1269562] 2019, the Inte rnational Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Integrated Addendum to E6 (R1): Guideline For Good Clinical Practice E6 (R2), the principles of the Declaration of Helsinki, and applicable regulations in the countries where 
the study will be conducted. I will not make changes to the protocol before consulting with 
Kowa Research Institute, Inc. or implement protocol changes without independent ethics 
committee approval except to eliminate an immediate ris k to patients. I agree to administer 
study treatment only to patients under my personal supervision or the supervision of a sub-investigator.  
I will not supply the investigational drug to any person not authorised to receive it. Confidentiality will be protected. Patient identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authoris ation from Kowa Re search Institute, Inc.  
   
Signature [CONTACT_789]   [INVESTIGATOR_904485] 3
Kowa Research Institute, Inc.  K-321
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269563] of Terms  ............................................................................................................................ 18  
1 Introduction ...................................................................................................................... 19  
2 Study Objectives ............................................................................................................... 22  
2.1 Primary Objective  ................................................................................................... 22  
2.2 Secondary Objectives .............................................................................................. 22  
2.3 Exploratory Objectives  ........................................................................................... 22  
3 Investigational Plan  .......................................................................................................... 23  
3.1 Study Design ........................................................................................................... 23  
4 Patient Selection and Discontinuation/Withdrawal Criteria  ............................................. 26  
4.1 Selection of Study Population ................................................................................. 26  
4.1.1  Inclusion Criteria  ..................................................................................... 26  
4.1.2  Exclusion Criteria  .................................................................................... 26  
4.2 Discontinuation of Treatment and Withdrawal of Patients From the Study ........... 28  
4.2.1  Reasons for Discontinuation or Withdrawal ............................................ 29  
4.2.2  Handling of Withdrawals  ......................................................................... 30  
4.2.3  Replacements  ........................................................................................... 30  
5 Study Drug Treatments  ..................................................................................................... 31  
5.1 Method of Assigning Patients to Treatment Groups ............................................... 31  
5.2 Treatments Administered  ........................................................................................ 31  
5.3 Identity of Study Drug ............................................................................................ 32  
5.4 Management of Clinical Supplies ........................................................................... 33  
5.4.1  Study Drug Packaging and Storage ......................................................... 33  
5.4.2  Study Drug Accountability  ...................................................................... 34  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269564] 2019 
 Page 5 5.5 Medication Errors  ................................................................................................... 34  
5.5.1  Treatment of Medication Errors  ............................................................... 34  
5.5.2  Overdose Management  ............................................................................ 34  
5.5.3  Missed Doses ........................................................................................... 35  
5.6 Masking  .................................................................................................................. 35  
5.6.1  Unmasking Treatment  .............................................................................. 35  
5.7 Treatment Compliance  ............................................................................................ 36  
5.8 Prior and Concomitant Therapy .............................................................................. 36  
5.8.1  Descemetorhexis of the Study Eye .......................................................... 37  
5.8.2  Rescue Surgical Procedures  ..................................................................... 37  
5.8.3  Prohibited and Restricted Concomitant Therapy ..................................... 37  
[IP_ADDRESS]  Prohibited and Restricted Surgical Intervention ...................................... 37  
[IP_ADDRESS]  Prohibited and Restricted Medication  ..................................................... 38  
6 Study Assessments and Procedures  .................................................................................. 39  
6.1 Eligibility Assessments and Procedures ................................................................. 42  
6.1.1  Medical History, Physical Examination, and Laboratory Assessments ... 42  
6.1.2  Descemetorhexis of the Study Eye .......................................................... 42  
6.2 Efficacy Assessments .............................................................................................. 42  
6.2.1  Corneal Endothelial Cell Density Measurement  ..................................... 42  
[IP_ADDRESS]  Non-Contact [CONTACT_386086]  .......................................................... 42  
[IP_ADDRESS]  Heidelberg Retina Tomography  ............................................................... [ADDRESS_1269565] Sensitivity  .................................................................................. 43  
6.2.7   ........................................................... 44  
6.3 Safety Assessments  ................................................................................................. 44  
6.3.1  Ocular Safety Assessments  ...................................................................... 44  
6.3.2  Adverse Events ........................................................................................ 45  
[IP_ADDRESS]  Definitions of Adverse Events  ................................................................. 45  
[IP_ADDRESS]  Eliciting and Documenting Adverse Events ............................................ 47  
[IP_ADDRESS]  Reporting Adverse Events  ....................................................................... 48  
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reactions ................................. 50  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269566] 2019 
 Page 6 [IP_ADDRESS]  Follow-Up of Adverse Events ................................................................. 50  
6.3.3  Vital Sign Measurements  ......................................................................... 50  
6.3.4  Eligibility  ................................................................................................. 51  
6.4 Safety Monitoring Committee ................................................................................ 51  
6.5 Pregnancy ................................................................................................................ 51  
6.6 Laboratory Analyses  ............................................................................................... 52  
6.6.1  Future Genetic Testing  ............................................................................. 52  
6.7 Sample Collections  ................................................................................................. 53  
7 Statistical and Analytical Plan  .......................................................................................... 54  
7.1 Primary Ef ficacy Endpoint ..................................................................................... 54  
7.2 Secondary Efficacy Endpoints ................................................................................ 54  
7.3 Exploratory Endpoints  ............................................................................................ 55  
7.4 Samp le Size Calculations  ........................................................................................ 55  
7.5 Analysis Sets ........................................................................................................... 56  
7.6 Description of Subgroups to be Analysed ............................................................... 56  
7.7 Statistical Analysis Methodology  ........................................................................... 56  
7.7.1  Analysis of Primary Efficacy Endpoint ................................................... 57  
7.7.2  Analysis of Secondary Efficacy Endpoints ............................................. 58  
7.7.3  Analyses of Exploratory Efficacy Endpoints ........................................... 59  
7.7.4  Safety Analyses  ........................................................................................ 60  
[IP_ADDRESS]  Adve rse Events  ........................................................................................ 60  
[IP_ADDRESS]  Vital Signs  ................................................................................................ 61  
[IP_ADDRESS]  Clinical Laboratory  .................................................................................. 61  
[IP_ADDRESS]  Intra -Ocular Pressure  ............................................................................... 61  
[IP_ADDRESS]  Slit-Lamp Biomicroscopy and Ophthalmoscopy ..................................... 61  
7.7.5  Other Analyses  ......................................................................................... 62  
[IP_ADDRESS]  Patient Demographics and Other Baseline Characteristics  ...................... 62  
[IP_ADDRESS]  Treatment Exposure and Compliance ...................................................... 62  
7.7.6  Interim Analyses  ...................................................................................... 62  
8 Data Quality Assurance  .................................................................................................... 64  
8.1 Data Management  ................................................................................................... 64  
9 Ethics  ................................................................................................................................ 66  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269567] of the Study .................................................................................. 66  
9.3 Patient Information and Consent ............................................................................ 66  
10 Investigator’s Obligations ................................................................................................ [ADDRESS_1269568] ......................................................................................................... 69  
10.5  Adherence to Protocol ............................................................................................ 70  
10.6  Adverse Events and Study Report Requirements ................................................... 70  
10.7  Investigator’s Final Report ..................................................................................... [ADDRESS_1269569] ................................................................................................................... 76  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269570] of Tables  
Table  5-1  Vial Contents by [CONTACT_904503] 1 to Visit 9 (Week 12) ......................................................... [ADDRESS_1269571] of Figures  
Figure 3-1  Study Design ................................................................................................... 24  
 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269572] 2019 
 Page 9 Protocol Synopsis  
Protocol Number:  
K-321-201 
Title:  
A Double- Masked, Randomised, Placebo- Controlled, Parallel -Group, 12- Week, Phase 2 
Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After 
Descemetorhexis in Patients with Fuchs Endothelial Corneal Dystrophy 
Sponsor:  
Kowa Research Institute, Inc.  
[ADDRESS_1269573] Morrisville, NC [ZIP_CODE]  
Study Phase:  
Phase 2  
Study Sites:  
Approximately 30 sites in the [LOCATION_002], Europe, and Australia 
Indication:  
The treatment of Fuchs endothelial corneal dystrophy after descemetorhexis 
Rationale:  
In Fuchs endothelial corneal dystrophy (FECD) , there is an increased rate of loss of 
endothelial cells, starting in the cent re of Descemet’s membrane and spreading to the 
periphery. There is an increased deposition of extracellular matrix on Descemet’s membrane, resulting in excrescences known as guttae, which are a marker of the condition. Guttae may coalesce and inhibit the migration of endothelial cells. Eventually the corneal endothelium ceases to function effectively, and the cornea begins to cloud, leading eventually to blindness.  
Currently, most patients undergoing keratoplasty for FECD have Stage 2 disease and the 
procedure starts with descemetorhexis, removing an area of the roughened and irregular Descemet’s membrane (including the central guttae) from the diseased cornea. The excised area is replaced wit h a graft of endothelial cells: either donor Descemet’s 
membrane with a thin layer of corneal stroma (Descemet strippi[INVESTIGATOR_43694] [DSEK]), or, increasingly commonly, donor Descemet’s membrane alone (Descemet’s membrane endothelial keratoplasty [DMEK]).  
Experience with failed grafts has indicated that even though there is an underlying abnormality of endothelial cells in FECD, areas of stroma exposed by [CONTACT_904504] -endothelialis ed and the migrated endothelial cells can maintain corneal 
transparency. Mathematical modelling of the healing of an inadvertent  diameter descemetorhexis in an elderly man without FECD suggested that normal healing is achieved by a redistribution of peripheral endothelial cells into the central defect without any increase in the number of endothelial cells. This led to the proposal that some cases 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269574] 2019 
 Page 12 During the follow-up period, patients will attend 5 study visits, starting at Week 16 
(Visit 10).  
  will determine central EC D by 
[CONTACT_904505] s of the corneal endothelium.  
Keratoplasty may be offered as a rescue surgical procedure to an enrolled patient if the investigator judges that endothelial healing is not complete at Visit 9 (Week 12), or earlier if the investigator considers that the  patient needs urgent treatment.  
Study Population:  
Inclusion Criteria:  
Each patient must meet all of the following criteria to be enrolled in this study: 
1. Is at least 18 years old at the screening visit (Visit 1).  
2. Has a diagnosis of FECD at Visit 1.  
3. Has co nfluent central guttae in the study eye that can be removed by [CONTACT_904506] a circular area of  diameter or less (at Visit 1).  
4. Has a study eye with best corrected visual acuity (BCV A) of 75 letters or fewer by 
[CONTACT_344603] ( ETDRS ) testing (Snellen equivalent of 
20/32 or worse) at Visit 1.  
5. The study eye descemetorhexis at Visit [ADDRESS_1269575] excised a central area with confluent guttae and a diameter of  Guidance for performing the 
study eye descemetorhexis and measurement of the excised area will be provided in 
the study manual.  
6. Can understand the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements before any study- specific assessment is performed.  
Exclusion Criteria:  
Patients meeting any of the following criteria will be excluded from the study:  
1. Is a female patient and any of the following is true:  
• is pregnant or lactating/breastfeeding, or  
• is not surgically sterile, not post-menopausal (no menses for the previous 12 
months), or not practising an effective method of birth control as determined by [CONTACT_093] (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).  
If a patient is female and of childbearing potential, she must have a negative urine pregnancy test result at Visit [ADDRESS_1269576]-menopausal, and a 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269577]-menopausal woman is defined as having had no menses for the previous 12 months 
(without a known cause). 
2. Has a study eye with confluent guttae in the periphery or confluent guttae outside the stripped area (individual guttae are allowed).  
Note that patients may have individual or small num ber of guttae remaining outside 
the stripped area, but there should be no areas of confluent guttae remaining after the 
descemetorhexis. For example, a patient who had [ADDRESS_1269578] on the non -study eye in 
the screening or treatment period. 
8. Has advanced corneal stromal oedema defined as the presence of widespread haze or bullae on slit -lamp examination. 
9. Has a study eye with central corneal thickness ≥ 670 μm.  
10. Has known severe comorbidities that may interfere with descemetorhexis (eg, a bacterial, viral, or fungal ophthalmic infection). 
11. Has any clinically significant ocular condition other than FECD or cataract that requires medication or ocular surgery . 
12. Has diabetes with poor blood sugar control (eg, HbA1c value > 8.5% ). 
13. Has used contact [CONTACT_72061] 7 days of Visit 1.  
14. Has hypersensitivity to any ophthalmic medication used for diagnosis or treatment, including eye drops containing antibiotic(s) or glucocorticoid(s).  
15. Has known hypersensitivity to any component of the study drugs. 
16. Has previously used ripasudil, netarsudil, or other ROCK inhibitors.  
17. Has used any investigational medications within [ADDRESS_1269579] result for drugs of abuse (opi[INVESTIGATOR_858], methadone, cocaine, amphetamines, barbi turates, or benzodiazepi[INVESTIGATOR_1651]) or alcohol at screening.  
19. Has donated more than 450 mL of blood within 60 days of Visit 1. 
20. Is a member or a family member of the professional or ancillary personnel working at the study site or the sponsor involved in the study. 
21. Has a concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opi[INVESTIGATOR_871].  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269580] 2019 
 Page 16 will be summarised  and listed with no statistical hypothesis testing performed. 
Continuous variables will be summarised  using the mean, the SD , median, minimum 
value, and maximum value. Categorical variables will be summarised  using frequency 
counts and percentages.  
Version and Date of Protocol: 
Version 1.0 (Original) , [ADDRESS_1269581] 2019 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269582] research organisation  
CS clinically significant  
CV curriculum vitae  
DMEK  Descemet membrane endothelial keratoplasty  
DSEK  Descemet strippi[INVESTIGATOR_904486]-of-study 
EOT  end-of-treatment  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FAS full-analysis set  
FDA  US Food and Drug Administration  
FECD  Fuchs endothelial corneal dystrophy 
GCP  Good Clinical Practice  
HbA1c  haemoglobin A1c  (glycated haemoglobin)  
HRT  Heidelberg retina tomography 
ICF informed consent form 
ICH International Council for Harmonisation  
IEC independent ethics committee  
IOP intra-ocular pressure  
IRB institutional review board 
IWRS interactive web response system  
LOCF  last-observation- carried -forward  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269583] 2019 
 Page 18 Abbreviation  Definition  
M/N  morning and night 
MD/E  mid-day and evening  
MedDRA  Medical Dictionary for Regulatory Activities  
MHRA  Medicines and Healthcare Products Regulatory Agency 
NCS  not clinically significant  
PPS per-protocol set  
QID [ADDRESS_1269584] of Terms  
Term  Definition  
Descemetorhexis  Removal of an area of roughened and irregular Descemet membrane 
along with central guttae (also referred to herein as Descemet 
membrane strippi[INVESTIGATOR_007])  
 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269585] Fuchs described a bilateral corneal dystrophy now referred to 
as Fuchs endo thelial corneal dystrophy (FECD). The primary defect in FECD  seems to be 
related to the endothelial cells that normally sit on a modified basement membrane (Descemet’s membrane) that lines the inner surface of the cornea.  
In the normal adult human cornea, the endothelial
  cell density (ECD) on Descemet’s 
membrane is in the range of 2,000 to 3,500 cells/mm2 (Ianchulev et al 2019) and the 
endothelial cells maintain the cornea in a state of relative dehydration, which preserves 
corneal transparency. During adulthood there is continuous loss of endothelial cells at an approximate rate of 0.6% per year. Since the number of endothelial cells cannot increase 
because of a state of mitotic arrest, gaps caused by [CONTACT_904507]. The function of the corneal endothelium 
can be maintained while the ECD is maintained above approximately 400 cells/mm
2. Below 
that threshold (due to disease, trauma or old age), there is decompensation of the endot helial 
pumpi[INVESTIGATOR_904487] a visual haze ( Van den Bogerd et al 
2018).  
In FECD , there is an increased rate of loss of endothelial cells, starting in the cent re of 
Descemet’s membrane and spreading to the periphery. There is an increased deposition of 
extracellular matrix on Descemet’s membrane, resulting in excrescences known as guttae, 
which are a marker of the condition. Guttae may coalesce and inhibit the migration of 
endothelial cells. Eventually the corneal endothelium ceases to function effectively, and the 
cornea begins to cloud, eventually leading to blindness ( Elhalis et al. 2010).  
There are clinical staging systems for FECD  that describe the pr ogression of the disease 
(Elhalis et al. 2010)
. Stage 1 is characterised by [CONTACT_904508], 
non-confluent, and asymptomatic. Guttae may also form in response to 
trauma, toxins, or infection and may not be indicative of FECD . Guttae appearing with age 
are considered a normal finding in the elderly if they appear in the periphery. In Stage 2 , 
central guttae start to coalesce and spread to the periphery and there is loss of endothelial cells, with ECD being inversely proportional to the number of guttae. The cells become much 
more variable in size and lose their regular shape (pleomorphism), and painless visual symptoms start to appear. The irregularity of the Descemet’s membrane, and particularly the 
presence of central confluent guttae, may lead to forward scatter of light in the eye, loss of 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269586] sensitivity, and impairment of visual acuity, even in the absence of oedema 
(Watanabe et al 2015). In the early stages of the disease, oedema  of the stroma causes 
blur
riness of vision in the morning that clears during the day, but this progr esses to 
permanent loss of visual acuity with glare. In Stage 3 , there is more marked corneal oedema 
and painful sub-epi[INVESTIGATOR_904488]. Rupture of the bullae disrupts the outer surface of the cornea and exposes the patient to risk o f infection. Finally, in Stage 4 , the 
cornea becomes opaque and new vessel growth may occur. In addition, there may be sub-epi[INVESTIGATOR_904489]-standing oedema . In this stage, the eye 
becomes blind, but the pain may subside ( Elhalis et al. 2010 ).
  
Fuchs endothelial corneal dystrophy is currently treated by a variety of keratoplasty 
techniques, including full-thickness cornea transplantation (for Stages 3 and 4) and 
2 techniques involving transplantation of a graft of donor endothelial cells on donor 
Descemet’s membrane. Currently, most patients undergoing keratoplasty for FECD  have 
Stage 2 disease and the procedure starts with descemetorhexis, removing an area of the 
roughened and irregular Descemet’s membrane (including the central guttae) from the 
diseased cornea. The excised area is replaced with a graft of endothelial cells: either donor 
Descemet’s membrane with a thin layer of corneal stroma (Descemet strippi[INVESTIGATOR_904490] [DSEK]), or, increasingly commonly, donor Descemet’s membrane alone (Descemet’s membrane endothelial keratoplasty [DMEK]).  
Experience with failed grafts has indicated that even though there is an underlying a
bnormality of endothelial cells in FECD , areas of stroma exposed by [CONTACT_904509]-endothelial ised and the migrated endothelial cells can maintain corneal transparency. 
Mathematical modelling of the healing of an inadvertent 5- mm diameter descemetorhexis in 
a
n elderly man without FECD  suggested that normal healing is achieved by [CONTACT_904510] ( Jul
lienne et al 2015 ). This led to the proposal that some cases of F ECD, 
particularly those with relatively preserved peripheral endothelial cells, can be treated by [CONTACT_904511] ( Garcerant et al 2019 ). 
T
here are limits to the ability of the endothelium to heal. In a recent analysis of  cases of 
patients who underw ent descemetorhexis without grafting as a possible treatment for FECD 
(compi[INVESTIGATOR_904491]), 31 (65%) out of [ADDRESS_1269587] as early as 1 month after the procedure ( Van den Bogerd et 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269588] 2019 
 Page 21 al 2018). If there was persistent oedema at 6 months, then it was unlikely to resolve. If 
corneal oedema did not clear, some patients’ corneas cleared without residual stromal 
damage after DMEK performed as rescue therapy between 4 and 8.5 months after 
Descemet’s membrane strippi[INVESTIGATOR_007] ( Van den Bogerd et al 2018). All keratoplasty procedures, 
including DMEK, are as
sociated with risks of graft detachment, graft failure or immune 
rejection. There is a medical need for medication that can speed healing after 
descemetorhexis and that can help establish a high, functional ECD to maintain corneal 
transparency.  
Ripasudil ophthalmic solution 0.4% (K-321) is a Rho- associated prot ein kinase (ROCK) 
inhibitor that has been marketed in Japan since December 2014 as Glanatec®, with twice 
daily  (BID)  dosing for glaucoma and ocular hypertension. Studies in endothelial cells have 
indicated that K -321 can lead to reduction of apoptosis, enhancement of cell proliferation, 
and increased rates of migration, all of which may support endothelial healing ( Kowa  
Company Ltd 2019). Moloney et al (2017)  first reported use of a ROCK inhibitor to promote 
healing in patients with FECD  treated with Descemet strippi[INVESTIGATOR_25583] (DSO). More recently, 
Macsai et al (2019)  reported results from a small study of 1 8 patients with FECD  and centra l 
confluent guttae of up to  diameter who underwent DSO and were subsequently treated 
with either ripasudil ophthalmic solution 0.4% four times daily (QID) or no ripasudil for 
2 months. Overall, patients who underwent DSO with ripasudil recovered vision more 
quickly   
 The patients in the no- ripasudil 
group had  
 while in the ripasudil group there was  
. In the short- term 
studies (8 weeks duration and less) for the development of Glanatec, there were no  
 
 
 (Kowa Company Ltd 2019).  
Kowa proposes to pursue developm
ent of K-321 (ripasudil ophthalmic solution) for the 
following indication: “the treatment of Fuchs endothelial corneal  dystrophy after 
descemetorhexis.” This will be the first Kowa-sponsored study in patients for this indication.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269589] of K -321 dosed for 12 weeks 
on central ECD in patients with FECD  after descemetorhexis.  
2.2 Secondary Objectives  
The secondary objectives of this study are the following:  
• to investigate the effect of K-321 on central ECD, corneal thickness, and corneal 
clarity in patients with FECD at each visit after descemetorhexis out to 52 weeks 
• to assess the safety and tolerability of K -321 in patients with FECD  at each visit after 
descemetorhexis out to 52 weeks 
2.3  Exploratory Objectives 
 
 
 
 
 
 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269590] 2019 
 Page 23 3 Investigational Plan  
3.1 Study Design  
This is a multi -centre, double-masked, randomised, parallel-group, placebo-controlled, 
2-period study of patients with FECD  after descemetorhexis. The study design is presented in 
Figure 3-1, and the schedule of study site activities (SOA) is presented in  Table  6-1.  
The first period is the treatment period, consisting of a screening visit within a 1 - to 4- week 
screening period, a descemetorhexis and randomisation visit, a 12- week full treatment period 
containing 7 interim visits (including 1 optional visit at Week 2) and an end-of- treatment 
(EOT) visit scheduled for Week 12. During the 2 weeks immediately following the EOT 
visit, each enrolled patient will taper dosing of study drug to zero ( Section 5.2).  
The second period is a follow-up observation period of 40 weeks, including the tapering phase and containing 4 interim visits and an end-of- study (EOS) visit. Patients are not to 
self-administer study drug after approximately Week 14. The maximum total study period for 
each enrolled patient is 56 weeks, with a maximum of 15 visits (including the 1 optional 
visit). Patients will be considered to have completed th e study with the completion of their 
EOS visit (scheduled for Week 52). The duration of the study is defined for each patient as the date signed written informed consent is provided through the last follow-up visit. 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269591] 2019 
 Page 24 There are 3 treatment groups: K-321 ophthalmic solution 0.4% dosed QID, K-321 
ophthalmic solution 0.4% dosed BID, and placebo. The procedures for randomly assigning study drug a re presented in Section  5.1. 
After obtaining informed consent at Visit 1, the investigator will select one eye as the study eye, and the patient will come back for the descemetorhexis operation and random 
assignment to treatment after 1 to 4 weeks (Visit 2). At Visit 2, each patient’s eligibility for 
study participation will be confirmed, including a successful descemetorhexis oper ation that 
meets the inclusion criteria (Section  4.1). Guidance for the descemetorhexis will be provided 
in the study manual. Recommended post -descemetorhexis concomitant therapy is described 
in Section 5.8.1. Documentation of the descemetorhexis is discussed in Section  6.1.  
After eligibility is confirmed, patients will be rando mly assigned to the 3 treatment groups 
(in a 1:1:1 ratio). All patients will be instructed to apply the study drug only to the study eye.  
Except on days of study visits on Day 1 through Week 12 (not including Visit 9) during the 
treatment period, study drug will be dosed by [CONTACT_904512] ( Section  5.2): morning (9 AM 
±1 hour
), mid -day (1 PM  ±1 hour), evening (5 PM  ±1 hour ), and night (9 PM ±1 hour). Each 
patient will be provided with 2 sets 
of colour-coded  one set to be applied 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269592] 2019 
 Page 25 morning and night (M/N)  and the other to be applied mid -day and evening (MD/E). See 
Section  5.4.[ADDRESS_1269593] been completed ; thereafter on those days , patients will start 
dosing with the dose closest in timing to the dosing regimen and continue with the remaining 
doses for the day. Additionally, on Visit [ADDRESS_1269594] apply the study drug within 
 after the end of the descemetorhexis procedure on Day  –1 (Visit 2). 
With the primary efficacy endpoint being assessed at Visit 9 (Week 12), if a patient applies 
any study drug on the day of Visit [ADDRESS_1269595] been completed, that 
patient’s Visit 9 should be rescheduled within the visit window allowa nce (eg, the next day). 
For visits other than Visit [ADDRESS_1269596] be recorded.  
At Visit 9 (Week 12), patients will enter the drug-tapering phase of the follow-up period , and 
new study drug will be dispensed without M/N  or MD/E  colour coding ( Section 5.2 ). All 
patients will self -administer their tapering -phase study drug BID (9 AM ±1 h and 9 PM  ±1 h) 
for a week, then once daily (9 AM ±1 h) for a week, and then will discontinue study drug. At 
Visit 9, patients will apply the first dose of study drug  of completing study 
measurements and will apply the second dose at night, as scheduled.  During the follow-up period, patients will attend 5 study visits ( Figure  3-1), starting at 
Week  16 (Visit 10).  
Study activities and assessments will be performed at study visits as described in  Table  6-1 
and in Section 6.   will determine 
central E CD by [CONTACT_904513] s of the corneal endothelium ( Table  11-1).  
Keratoplasty may be offered as a rescue surgical procedure to an enrolled patient if the 
investigator judges that endothelial healing is not complete at Visit 9 (Week 12),  or earlier if 
the investigator considers that the patient needs urgent treatment (Section  5.8.2).  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269597] 2019 
 Page 26 4 Patient Selection and Discontinuation/Withdrawal Criteria 
4.[ADDRESS_1269598] meet all of the following criteria to be enrolled in this study: 
1. Is at least 18 years old at the screening visit (Visit 1).  
2. Has a diagnosis of FECD  at Visit 1 . 
3. Has confluent central guttae in the study eye that can be removed by [CONTACT_904514] a circular area of  diameter or less (at Visit 1).  
4. Has a study eye with best corrected visual acuity ( BCV A) of 75 letters or fewer by 
[CONTACT_344603]  (ETDRS ) testing (Snellen equivalent of 
20/32 or worse) at Visit 1.  
5. The study eye descemetorhexis at Visit [ADDRESS_1269599] excised a central area 
with confluent guttae and a diameter of  Guidance for performing the 
study eye descemetorhexis and measurement of the excised area will be provided in the study manual.  
6. Can understand the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements before any 
study- specific assessment is performed.  
4.1.2 Exclusion Criteria  
Patients meeting any of the following criteria will be excluded from the study: 
1. Is a female patient and any of the following is true:  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269600] 2019 
 Page 27 • is pregnant or lactating/breastfeeding , or  
• is not surgically sterile, not post- menopausal (no menses for the previous 
12 months), or not practising an effective method of birth control as 
determined by [CONTACT_3170] (eg, oral contraceptives, double barrier 
methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).   
If a patient is female and of childbearing potential, she must have a negative urine pregnancy test result at Visit [ADDRESS_1269601]-menopausal woman is defined as having had no 
menses for the previous 12 months (without a known cause). 
2. Has a study eye with confluent guttae in the periphery or confluent guttae outside the 
stripped area (individual guttae are allowed).  
Note that patients may have individual or small number of guttae remaining outside 
the stripped area, but there should be no areas of confluent guttae remaining after the 
descemetorhexis. For examp le, a patient  who had [ADDRESS_1269602] on the non-study eye in 
the screening or treatment period. 
8. Has advanced corneal stromal oedema defined as the presence of widespread haze or bullae on slit -lamp examination. 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269603] 2019 
 Page 28 9. Has a study eye with central corneal thickness ≥ 670 μm.  
10. Has known severe comorbidities that may interfere with descemetorhexis (eg, a 
bacterial, viral, or fungal ophthalmic infection). 
11. Has any clinically significant ocular condition other than FECD or cataract that requires medication or ocular surgery (described in Section  5.8.3). 
12. Has diabetes with poor blood sugar control (eg, HbA1c value > 8.5% ). 
13. Has used contact [CONTACT_72061] 7 days of Visit 1. 
14. Has hypersensitivity to any ophthalmic medication used for diagnosis or treatment, including eye drops containing antibiotic(s) or glucocorticoid(s).  
15. Has known hypersensitivity to any component of the study drugs. 
16. Has previo usly used ripasudil, netarsudil, or other ROCK inhibitors.  
17. Has used any investigational medications within [ADDRESS_1269604] result for drugs of abuse (opi[INVESTIGATOR_858], methadone, cocaine, amphetamines, barbiturates, or benzodiazepi[INVESTIGATOR_1651])  or alcohol at screening.  
19. Has donated more than [ADDRESS_1269605] study visit attended.  
There are 3 scenarios that result in interruption of the treatment regimen. Interruption of 
treatment is defined as a temporary stoppi[INVESTIGATOR_904492], due to an AE or any other reason. Early discontinuation of treatment is 
defined as permanent stoppi[INVESTIGATOR_904493] 9, scheduled 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269606] 2019 
 Page 29 for We ek 12. Investigators will strive to ensure that a patient who has interrupted treatment 
for a particular reason will not discontinue treatment unless discontinuation is medically 
imperative in the investigator’s judgement. Early withdrawal from the study is defined as 
failing to complete Visit 14, scheduled for Week 52.  
Study drug administration may be discontinued early at the discretion of the investigator (or 
designee) if the patient does not tolerate the dosing regimen or if, in the investigator’s 
judgement , the patient’s health may be jeopardise d by [CONTACT_904515]. Patients 
who discontinue treatment during the study will be encouraged by [CONTACT_904516], and study d ata will be 
collected for these patients per protocol. Every effort must  be made to keep patients in the 
study (see Section  5.8.2 for a discussion of treatment discontinuation  after rescue surgical 
procedures) .  
4.2.[ADDRESS_1269607]  be made to keep patients in the study. The reasons for patients 
discontinuing treatment or withdrawing early will be recorded.  
A patient may discontinue treatment or be discontinued from treatment for any of the 
following reasons:  
1. The patient does not meet the protocol inclusion or exclusion criteria. 
2. The patient is non-compliant with the protocol. 
3. The patient has a serious or intolerable AE that, in the investigator’s opi[INVESTIGATOR_1649], requires withdrawal from the study.  
4. The patie nt has symptoms or an intercurrent illness not consistent with the protocol 
requirements or that justify withdrawal.  
5. The patient undergoes rescue keratoplasty (Section 5.8.2).  
6. Other reasons (eg, pregnancy, development of contraindications of use of study drug). 
A patient may be withdrawn from the study for any of the following reasons: 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269608] a positive benefit- to-risk ratio.  
4.2.2 Handling of Withdrawals  
 Patients who withdraw from the study or who are withdrawn from the study will no longer 
receive study drug. When a patient withdraws or is withdrawn from the study, the reason(s) for withdrawal shall be recorded by [CONTACT_904517] (eCRF). Whenever possible, all patients who withdraw from the study early 
will undergo all EOS  assessments. Patients who fail to return for final assessments will be 
contact[CONTACT_904518] [ADDRESS_1269609] them comply with the protocol. 
It is vital to obtain follow -up data on any patient withdrawn because of an AE or serious AE 
(SAE). In every case, efforts must be made to undertake protocol- specified safety follow -up 
procedures. 
4.2.[ADDRESS_1269610] -selected study eye, is presented in 
Section  [IP_ADDRESS].  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269611] been completed; thereafter on those days, patients will start 
dosing with the dose closest in timing to the dosing regimen and continue with the remaining 
doses for the day. Additionally, on Visit [ADDRESS_1269612] apply study drug within 
 after the end of the descemetorhexis procedure on Day  –1 (Visit 2). 
With the primary efficacy endpoint being assessed at Visit 9 (Week 12), if a patient applies 
any study drug on the day of Visit [ADDRESS_1269613] been completed, that 
patient’s Visit 9 should be rescheduled within the visit window allowance (eg, the next day). 
For visits  other than Visit [ADDRESS_1269614] be recorded.  
At Visit 9 (Week 12), patients will enter the drug -tapering phase of the follow-up period, and 
new study drug will be dispensed without M/N  or MD/E  colour coding ( Section 5.2 ). All 
patients will self -administer their tapering -phase study drug BID (9 AM ±1 hour and 
9 PM  ± 1 hour) for a week, then once daily (9 AM ± 1 hour) for a week, and then will 
discontinue study drug. At Visit 9, patients will apply the first dose of study drug  
 of completing study measurements and will apply the second dose at night, as 
scheduled. However, if the first dose will be applied after [ADDRESS_1269615]  instil 1 drop to the study eye only and then close the eyelids, 
pressin g on the lacrimal punctum. Patients will be advised to keep the eye closed for 
1 to 5 minutes before opening the eye. Any other concurrent ocular medication(s) must be 
applied at least 5 minutes following instillation of study drug. Patients will be traine d by [CONTACT_904519]. 
5.3 Identity of Study Drug 
The K -321 ophthalmic solution contains ripasudil 0.4% (4.896 mg/mL of ripasudil 
hydrochloride hydrate, equivalent to 4.0 mg/mL as the free base) in a solution also containing 
the excipi[INVESTIGATOR_904494] a pH in the range of 
5.0 to 7.0. The solution is isosmotic to normal saline, clear, colour less, and  The 
placebo ophthalmic solution is identical in appearance, osmolarity, and pH to the K-321 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269616] 2019 
 Page 34 selected clinical supply depots where shipments to clinical sites are managed via the IWRS  
system.   
The mater ials schedule will be prepared by [CONTACT_904520]. At the time of randomis ation, the IWRS will assign 
each patient a study drug kit corresponding to the patient’s randomly assigned treatment 
based on the drug supply inventory that is available at the site. The kit will be identified by a 
unique kit number that is separate from the patient or randomisation numbers. The IWRS 
will administer study drug dispensing at each visit indicated in Table  6-1. 
5.4.[ADDRESS_1269617] ions on how to administer their assigned ophthalmic 
solution and how to avoid contaminating the solution, and they will be observed instilling their own drops by [CONTACT_7893]. Re- education on the proper administration 
procedure will be given to patients by [CONTACT_904521]. To minim ise medication errors during the 12 -week treatment phase,  and 
 will be colour-coded differently for M/N and MD/E doses.  
5.5.[ADDRESS_1269618]  be provided 
as dictated by [CONTACT_102]’s clinical status.   
5.5.2 Overdose Management 
A symptomatic overdose from topi[INVESTIGATOR_475284], as no overdose was observed during the development of Glanatec (Kowa Company Ltd 2019). Patients will be 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269619] be reported as AEs 
(or SAEs) in the eCRF. In the event of overdose, the appropriate supportive clinical care must  
be provided as dictated by [CONTACT_102]’s clinical status  
5.5.3 Missed Doses  
If a dose is missed, patients will be advised as follows:  
• If you notice you missed a dose 2 hours or less after a scheduled dose time, dose immediately  
• If you notice you missed a dose more than [ADDRESS_1269620] access to treatment assignments; all other parties involved in the study will be fully masked. 
5.6.1 Unmasking Treatment 
A patient’s treatment assignment will not be unmasked for  the investigator or study site staff 
until the EOS  unless medical treatment of the patient depends on knowing the study 
treatment the  patient received. In the rare event that unmasking is needed because of a 
medical emergency, the investigator may unmask an individual patient through the IWRS. Reasons for treatment unmasking must be clearly explained and justified in the eCRF. The 
date on which the code was broken together with the identity of the person responsible must 
also be documented. 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269621] 2019 
 Page 37 Any concomitant medication o r surgical procedure deemed necessary for the welfare of the 
patient during the study may be given at the discretion of the investigator. However, it is the 
responsibility of the investigator to ensure that details regarding the medication and surgical 
treatment are recorded in full in the eCRF.  
5.8.1 Descemetorhexis of the Study Eye 
As a condition of participating in the study, each patient will undergo descemetorhexis of the 
investigator- selected study eye at Visit 2 ( Day –1). See Section  6.1.[ADDRESS_1269622]-descemetorhexis concomitant therapy consists  
 instilled  and 
 instilled  
. However, an investigator will be 
able to add  dosing after  if the 
investigator judges it necessary. When more than 1 different eye drop is administered (including study drug), the study drug must  be administered first, followed by [CONTACT_163393]-study 
eye drop(s)  after at least [ADDRESS_1269623] passed  (Section  5.2).  
A patient must not be randomly assigned to study drug unless the excised diameter satisfies 
inclusion c riterion  5 (Section  4.1.1).  
5.8.2 Rescue Surgical Procedures  
Penetrating keratoplasty or endothelial keratoplasty may be offered as rescue surgical 
procedures to an enrolled patient if the investigator judges that endothelial healing is not 
complete at Week 12 (Visit 9), or earlier if the investigator considers that the patient needs 
urgent treatment. If the rescue surgery is performed, the dosing with study drug must be 
discontinued immediately (without tapering) and the patient will attend all planned study 
visits including the follow -up period. 
5.8.3 Prohibited and Restricted Concomitant Therapy 
[IP_ADDRESS]  Prohibited and Restricted Surgical Intervention 
Throughout the study, study eyes must  not undergo any surgical intervention other than the 
descemetorhexis at Visit 2. Non -study eyes must not undergo any surgical treatment for 
FECD  or cataract in the screening or treatment periods, but they can be surgically treated 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269624] study descemetorhexis, then the 
patient can be enrolled using the second eye to qualify. 
Punctal occlusion plugs are considered to be surgical interventions.  
[IP_ADDRESS]  Prohibited and Restricted Medication  
The following medications and drugs identified as exclusion criteria are prohibited for use by 
[CONTACT_904522]: 
• Netarsudil or other ROCK inhibitors  
• Eye drops and ointments containing 5% sodium chloride 
• Devices to improve any ocular symptoms (eg, TrueTear®, Lipi[INVESTIGATOR_69177]®, etc)  
• Drugs of abuse (opi[INVESTIGATOR_858], methadone, cocaine, amphetamines, barbiturates, or benzodiazepi[INVESTIGATOR_1651]) or more than [ADDRESS_1269625] drinks of alcohol per day 
• Contact [CONTACT_13276] (except non-study eye) 
• Any ophthalmic solution beside s artificial tears, over -the-counter anti -allergic 
ophthalmic products, study drug, or drugs prescribed by [CONTACT_904523] 
• Any investigational drug besides study drug 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269626] 2019 
 Page 39 6 Study Assessments and Procedures  
Before performing any study procedures, all potential patients will sign an informed consent 
form (ICF). Patients will have the opportunity to have any questions answered before signing 
the ICF. The investigator must address all questions raised by [CONTACT_11346]. The investigator or 
designee will also sign the ICF.  
The SOA is presented in Table  6-1. Detailed instructions for study site activities will be 
provided in the study manual.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269627] 2019 
Page 40 Table  6-1 Schedule of Study Site Activities  
 Activity Screening  Treatment Period  Follow -Up Period  
Time P oint Day -28 Day –1 Day 1  Week 1  Week2  Week 3  Week 5  Week 7  Week 9  Week 12  Week 16  Week 20  Week 24  Week 38  Week 52  
Visit Window (Day)  -[ADDRESS_1269628] (if 
applicable)   X a         X     
Laboratory sampling   X         X      
Eligibility evaluation  X X b              
Descemetorhexis with photo or video documentation   X              
Randomis ation   X              
Dispense study drug   X X  X X X X X      
st udy drug c    X (X) d X X X X X X     
Study drug administration    X X (X) d X X X X X      
Slit-lamp evaluation  X X a X X (X) d X X X X X X X X X X 
Corneal ECD measurement e 
(specular microscopy, 
non-contact [CONTACT_24975])  X   X (X) d X X X X X X X X X X 
Corneal ECD measurement 
by [CONTACT_84888] T f (X)   (X) (X) d (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269629] 2019 
 Page 42 6.1 Eligibility Assessments and Procedures 
6.1.1 Medical History, Physical Examination, and Laboratory 
Assessments  
Medical history and assessments of concomitant disease, physical examination and vital sign 
measurements, urine screening for drugs of abuse, pregnancy screening for patients of 
childbearing potential , and clinical laboratory assessments will be conducted at screening 
primarily to assess eligibility to participate in the study. The limited physical examination includes a review of the patient’s medical and medication history and subsequent evaluation 
of relevant body system complaints. In case of relevant findings, full evaluation of the condition needs to be conducted. Demographics information will be collected at screening as 
follows: age, race, iris colour, and sex.  
6.1.2 Descemetorhexis of the Study Eye 
Each patient will undergo descemetorhexis of the investigator- selected study eye at Visit 2 
(Day –1). A digital photo of the study eye must be taken immediately before and immediately 
after descemetorhexis at Visit 2. The investigator will perform descemetorhexis to remove 
central confluent guttae, removing an area of Descemet membrane with a diameter of  
 The longest diameter and the shortest diameter must be recorded in  the eC RF. The 
procedure must be recorded by [CONTACT_904524]. Also, immediately after the operation, the stripped area will be recorded by 
[CONTACT_904525]. Detailed guidance for performing the study eye descemetorhexis will be provided in the study manual. 
Recommended post-descemetorhexis concomitant therapy is described in Section 5.8.1. 
6.2 Efficacy Assessments  
6.2.1 Corneal Endothelial Cell Density Measurement 
[IP_ADDRESS]  Non-Contact [CONTACT_904526] -contact [CONTACT_239796]. The study eye must be 
assessed at all study visits  as indicated in Table  6-1, whereas the non-study eye must be 
measured only at Visit [ADDRESS_1269630] be used for all study visits 
for a given patient throughout the study. All s pecular microscope images taken  will be sent to 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269631] 2019 
 Page 43 the  for analysis via a designated portal site. Please s ee the study manual for detailed 
instructions.  
[IP_ADDRESS]  Heidelberg Retina Tomography  
Heidelberg retina tomography (HRT) of the study eye will be performed according to the 
schedule in Table  6-[ADDRESS_1269632] be recorded. See the study manual f or detailed instructions.  
6.2.3 Corneal Oedema   
Corneal oedema of the study eye will be categor ised by [CONTACT_14198][INVESTIGATOR_018], stromal, or endothelial, 
and assessed by [CONTACT_904527].   
6.2.4 Corneal Morphology  
Corneal morphology of the study eye wi ll be assessed by [CONTACT_904528]® or Bausch 
and Lomb Orbscan®. If the site has both instruments, the OCULUS Pentacam will be used. 
The same instrument must be used for all study visits for a given patient throughout the 
study. All data and images must be recorded.  
6.2.[ADDRESS_1269633] sensitivity of the study eye will be assessed using the VectorVision CSV -1000 
instrument if the necessary equipment is available at the study site before the start of the 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269634] 2019 
 Page 45  
6.3.2 Adverse Events 
[IP_ADDRESS]  Definitions of Adverse Events  
An AE is defined as any untoward medical occurrence in a patient enrolled into this study 
regardless of its causal relationship to study drug. An AE can therefore be any unfavourable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medici nal product, whether or not considered related 
to the medicinal product. Patients will be instructed to contact [CONTACT_904529]. 
An AE  may include the following:  
• Exacerbation of a pre‑existing disease or symptom 
• Increase in frequency or intensity of a pre‑existing event or condition  
• A condition detected or diagnosed after study drug administration even though it may 
have been present prior to the start of the study 
An AE  does not include the following:  
• Medical or surgical procedures (although the condition that leads to the procedure 
must  be reported as an AE) 
• Pre‑planned medical procedures (eg, planned surgical interventions, investigations, 
social and/or convenience hospi[INVESTIGATOR_56183])  
• Pre‑existing disease or conditions present at the time of signing the I CF are 
considered concurrent medical conditions and must  not be recorded as an AE 
The investigator must  attempt to establish a diagnosis of the event based on signs, symptoms, 
and other clinical information. In such cases, the diagnosis must  be documented as the AE 
and not as the individual signs or symptoms.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269635] the AE or investigation abnormality in the eCRF 
regardless of the relationship to the study drug (ie, the AE will be recorded whether or not it 
is considered related to the study drug). 
The criteria for determining whether an abnormal objective test finding must  be reported as 
an AE are as follows:  
• The t est result is associated with accompanying symptoms  
• The t est result requires additional diagnostic testing or medical/surgical intervention  
• The t est result leads to a change in study drug dosing or discontinuation from the 
study, significant additional concomitant drug treatment or other therapy and/or 
• The test  result leads to any of the outcomes i ncluded in the definition of an SAE 
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
require reporting as an AE. An abnormal test result that is determined to be an error or 
artefact does not require reporting as a n AE. 
A treatment -emergent AE (TEAE) is defined as any event not present before exposure to 
study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. 
An SAE is defined as any event that  
• results in d eath.  
Any death resulting from an AE occurring during the study period or within [ADDRESS_1269636] dose of the study drug, even if the death appears to be completely unrelated to the 
study or study drug. 
• is immediately life threatening .  
The term ‘life‑threatening’ refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269637] 2019 
 Page 47 • requires inpatient hospi[INVESTIGATOR_218747] .  
The term ‘hospi[INVESTIGATOR_11956]’ means a h ospi[INVESTIGATOR_904495]; prolongation 
means delay of a planned or anticipated discharge date by [CONTACT_2669] 1 overnight stay. 
Adverse events which require attendance at hospi[INVESTIGATOR_307] b ut do not require admission may be 
considered medically important.  
• results in persistent or significant disability/incapacity . 
• results in impairment, damage, or disruption in the study patient’s body function or structure, or physical ability or quality of life.  
• is a congenital anomaly/birth defect .  
Additionally, events in which there is suspi[INVESTIGATOR_904496] i s a medically import ant event . 
• Is medically important: a n event that may not be immediately life‑threatening or fatal or 
result in hospi[INVESTIGATOR_11956], but may require intervention to prevent one of the serious outcomes listed above.  
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias; convulsions that do not result in hospi[INVESTIGATOR_11956]; 
or development of drug dependency or drug abuse.  
[IP_ADDRESS]  Eliciting and Documenting Adverse Events 
The investigator is responsible for reporting AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance. Serious AEs 
will be collected from the time that the patient gives consent to participate in the study until 
[ADDRESS_1269638] been 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269639] 2019 
 Page 48 hospi[INVESTIGATOR_904497], had any accidents, had any eye surgery, used any new medications, or changed 
concomitant medication regimens (both prescription and over-the-counter medications).  
In addition to patient observations, AEs identified from any study data (eg, laboratory values, 
physical examination findings) or identified from review of other documents  that are 
relevant to patient safety will be documented on the AE page in the eCRF.  
[IP_ADDRESS]  Reporting Adverse Events 
All AEs reported or observed  will be recorded on the AE page of the eCRF. Information to 
be collected includes event term, time of onset, date of resolution of the event, seriousness, 
severity, relatedness to study drug, any required treatment or evaluations, and outcome.  
The investigator will assess the severity of the event. The severity (intensity) of AEs must  be 
classified using the following criteria:  
• Mild : An AE  that is easily tolerated by [CONTACT_102], causes minimal discomfort, and 
does not interfere with everyday activities  
• Moderate : An AE that causes enough discomfort to interfere with normal everyday 
activities and may require intervention  
• Severe: An AE  that prevents normal everyday activities (treatment or intervention 
will usually be required).  Severe events are usually incapacitating  
When changes in the severity of an AE occur more frequently than once a day, the maximum 
intensity for the event must be noted for that day. Any changes in intensity of signs and 
symptoms over multiple days will be captured by [CONTACT_904530], with the amended 
intensity grades and the dates (and time, if known) of the change(s). Changes in the intensity 
of an AE must be documented to allow an assessment of the duration of the event at each 
level of intensity.  
The investigator will assess the causal relationship between the study medication and the AE 
and decide whether, in his or her qualified medical judgement, there is a rea sonable 
possibility that the event may have been caused by [CONTACT_5257]. There are 2 categories of 
causality:  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269640] 2019 
 Page 49 • Unrelated : If no valid reason exists for suggesting a relationship, or the event may 
plausibly be related to the patient's clinical condition, an underlying disease or other 
medication taken by [CONTACT_102], then the AE must  be considered unrelated.  
• Related : If there is any valid reason for supposing that there is a relationship between 
the study medicine and the AE, especially if the even improves on withdrawal of the 
drug (de-challenge) or recurs on recommencement of therapy (re- challenge), then the 
AE must  be considered related. The AE must  not be considered related simply 
because it is not possible to rule out an association between the AE and  the study 
drug. 
The investigator’s assessment of an AE’s relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study. If there is any doubt as to whether a clinical observation is an AE, the event must be 
reported. 
The action taken with the study medication must  be recorded as treatment continued, 
treatment interrupted, or treatment discontinued. If the patient is no longer taking study 
medication at the time of the event, then action taken must  be recorded  as not applicable.  
All AEs will be followed to adequate resolution. The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code all AEs.  
Any AE that meets SAE criteria (Section  [IP_ADDRESS]) must be reported to the  
Pharmacovigilance Department immediately (ie, within 24 hours ) after the time site staff first 
learn about the event, using the electronic data capture (EDC) system . If for any reason the 
EDC is not available to the study site, the following contact [CONTACT_904531]: 
  Pharmacovigilance Department  
  
  
If the initial contact [CONTACT_904532], the SAE must still be reported, urgently, using the EDC system when it becomes 
available. Details on SAE reporting are presented in the study manual.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269641] 2019 
 Page 50 [IP_ADDRESS]  Suspecte d Unexpected Serious Adverse Reactions  
The sponsor will promptly evaluate all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) against cumulative product experience to identify and expeditiously communicate 
possible new safety findings to investigators, IRBs/IECs, and applicable health authorities 
based on applicable legislation.  
To determine reporting requirements for single S[LOCATION_003]R cases, the sponsor will assess the expectedness of these events using the Reference Safety Information section of the study 
drug investigator's brochure.  
The sponsor will compare the severity of each S[LOCATION_003]R and the cumulative event frequency 
reported for the study with the severity and frequency reported in the applicable reference 
document. 
[IP_ADDRESS]  Follow -Up of Adverse Events  
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
resolution, until the investigator deems the event to be chronic or not clinically significant (NCS) , or until the patient is considered stable. Adverse events that are ongoing at the time of 
the EOS visit are to be followed for 30 days or until resolution, until the investigator deems the no longer clinically significant (CS) , or until the investigator considers the patient’s 
condition stable. 
6.3.3 Vital Sign Measurements 
The fo llowing vital signs will be measured:  
• Blood pressure (measured supi[INVESTIGATOR_050], systolic and diastolic [mm Hg])  
• Pulse (beats per minute)  
• Body temperature (°F) 
• Height (cm) and body weight (kg). Height is to be measured at s creening only. 
Supi[INVESTIGATOR_9204], pulse , and body temperature (°F) will be recorded after the patient has 
been recumbent and at rest for at least 5 minutes.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269642] 2019 
 Page 51 6.3.4 Eligibility  
Eligibility will be evaluated at screening (Visit 1) and post-operatively on Day –1 (Visit 2). 
Patients must meet all inclusio n criterion and no exclusion criteria to be assigned study drug.  
6.4 Safety Monitoring Committee 
There will be no safety monitoring committee.  
6.5 Pregnancy 
Female patients of childbearing potential (defined in inclusion criterion 5 of Section  4.1.1) 
are required to use effective contraception throughout the study. 
Acceptable methods of contraception for female patients include oral contraceptives, other 
hormonal contraceptives (vaginal products, skin patches, or implanted/injectable products), 
or mechanical products such as an intrauterine device or barrier methods (diaphragm, 
condoms, spermicides). Note : female patients who are actively practi sing abstinence or who 
have a partner that is  sterile (eg, vasectomy) will be permitted to participate in the study 
without contraception use. 
Pregnancy is not regarded as an AE unless there is a suspi[INVESTIGATOR_49850] a contraceptive m edication. Any pregnancy that 
occurs during study participation must be reported using a clinical study pregnancy form. To ensure patient safety, each pregnancy must be reported to sponsor within [ADDRESS_1269643] be followed up to determine outcome (including spontaneous miscarriage, elective termination, normal birth, or congenital 
abnormality) and status of mother and child even if the patient was discontinued from the 
study. Pregnancy complications and elective terminations for medical reasons must be 
reported as an AE or SAE. Spontaneous miscarriages and congenital abnormalities of the 
child must be reported as an SAE. 
Any SAE occurring in association with a pregnancy, brought to the investigator’s attention 
after study completion, and considered by [CONTACT_904533], must be promptly reported to sponsor. 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269644] 2019 
 Page 52 6.6 Laboratory Analyses 
Routine laboratory analyses will be performed by a central laboratory and will include the 
following assessments:  
• Haematology : haemoglobin, haematocrit, red blood cell count, white blood cell 
count with differential, mean corpuscular volume, mean corpuscular haemoglobin, 
mean corpuscular h aemoglobin concentration, and absolute platelet count. 
• Clinical chemistry : total protein, sodium, potassium, chloride, albumin, glucose, 
HbA1c, blood urea nitrogen, creatinine, bilirubin (total and direct), alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, 
γ-glutamyltransferase, lactate dehydrogenase. 
• Urinalysis : pH, glucose, ketones, specific gravity, nitrite, protein, bilirubin, 
urobilinogen, and blood. Microscopic urinalysis will be performed if urinalysis results are abnormal.  
Urine  pregnancy testing will be performed for all patients of childbearing potential before 
descemetorhexis at Visit 2 and at Visit 10.  
Urine screening for drugs of abuse (opi[INVESTIGATOR_858], methadone, cocaine, amphetamines, barbiturates 
benzodiazepi[INVESTIGATOR_1651]) and alcohol will be performed by [CONTACT_5230].  
6.6.1 Future Genetic Testing  
A 6-mL blood sample will be obtained at Visit 1 for archiving and future genetic testing 
(Section  2.3). The blood sample will be collected only at sites in countries where allowed by 
[CONTACT_904534]/IEC and relevant regulatory authorities.  
Results of genetic testing will not be reported to the patient, relatives, or attend ing physician, 
and they will not be recorded in the participant's medical record. The participant may 
withdraw consent for genetic testing at any time up to analysis, even after the samples have 
been obtained. In the event of withdrawal of consent, the bio- repository will be notified to 
pull and destroy the sample. 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269645]  be performed according to local laboratory 
requirements and consistent with detailed procedures described in the study manual. 
The volume of blood sampled is planned to be less than 20 mL in a single day and less than 
35 mL over the entire study.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269646] 
measurements taken during the screening period (before Visit 2).  
7.1 Primary Efficacy Endpoint  
The primary efficacy endpoint is the centra l corneal ECD at Week 12 as assessed by [CONTACT_941] 
 
7.2 Secondary Efficacy Endpoints 
Secondary efficacy endpoints include: 
• Central corneal thickness change from baseline to each subsequent visit  
• Percent change of central corneal thickness from baseline to each subsequent visit 
• Central corneal ECD at each visit  
• Number and percentage of patients who achieve central corneal ECD of 700 cells/mm
2 or more at each visit  
• Time to achieve central corneal ECD 700 cells/mm2 or more  
• Number and percentage of patients who achieve cornea clearance at each visit where corneal clearance is defined as patients achieving a cornea thickness less than or 
equal to baseline cornea thickness and who have no corneal oedema  
o Number and percentage of  patients who achieve cornea thickness less than or 
equal to baseline cornea thickness  
o Number and percentage of patients who achieve no corneal oedema 
• Time to cornea clearance  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269647] 2019 
 Page 55 o Time to return of cornea thickness to less than or equal to baseline cornea 
thickness 
o Time to no corneal oedema  
7.3 Exploratory Endpoints  
Exploratory endpoints include the following:  
• BCV A (letters) by [CONTACT_904535]   
• Time to achieve BCV A by [CONTACT_904536]  
  
• Number and percentage of patients who achieve  or more 
improvement (BCV A by [CONTACT_63365]) 
• corneal ECD at   
•  corneal ECD change from  at   
• Percent change of  corneal ECD from  at  
• Changes in  parameters from    
• Contrast sensitivity change (log values) from     
•  domain and total scores change from    
7.[ADDRESS_1269648] a difference of  in the 
measurement in the corneal ECD at Week 12 between K -321 0.4% QID/BID and placebo 
groups with a power of  for Step [ADDRESS_1269649] with a 0.050 two- sided significance level with closed testing procedures. 
Sample size was calculated by [CONTACT_167889]. For the simulation, based on the existing literature, placebo was assumed to be distributed normally with  
 and K-321 was assumed to be distributed normally with  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269650] 2019 
 Page 56  Proportion of unmeasurable value of Week 12 due to corneal oedema and 
propor
tion of  value of Week 12 due to the withdrawal were assumed to be about 
10% and about 5%, respectively. 
7.5 Analysis Sets 
The following analysis sets will be used in the statistical analyses.  
Full-analysis set (FAS): The FAS will consist of all participants who have a successful 
descemetorhexis procedure performed, were randomly assigned to receive double- mask 
study drug, received at least one dose of study drug in the study eye, and have at least one 
assessment of central corneal ECD  performed after the descemetorhexis procedure on the 
study eye. (An assessment of “cannot perform due to corneal oedema ” is considered a valid 
assessment for inclusion in the FAS.) All analyses using the FAS will group participants accor ding to randomise d treatment.  
Per-protocol set (PPS): The PPS will consist of all FAS participants who complete the 
12-week dosing treatment period for the study eye (for the primary analysis only), have at 
least 80% compliance with study treatment for th e study eye, have not taken any prohibited 
medication, and have no major protocol deviations. Patients who receive rescue therapy will be considered to have completed study treatment for inclusion in the PPS. All analyses using 
the PPS will group participa nts according to treatment actually received.   
Safety set (SFS) : The safety set will consist of all participants who received any study drug. 
All analyses using the safety set will group participants according to treatment actually received.  
The FAS will b e the primary analysis set for efficacy analyses. Selected efficacy analyses 
will be repeated for the PPS. Safety will be summarised using the SFS.  
7.6 Description of Subgroups to be Anal ysed  
Due to the small sample size, no subgroup analyses are planned.  
7.7 Statistical Analysis Methodology  
Statistical analysis will be performed using SAS software Version 9.4 or later. Continuous variables will be summarised using the mean, the SD , median, minimum value, and 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269651] 2019 
 Page 57 maximum value. Categorical variables will be summarised using frequency counts and 
percentages. Unless otherwise noted, the denominator to determine the percentage of 
participants in each category will be based on the number of participants with available data. 
Selected ordinal data may be summarised using both descriptive statistics and counts and 
percentages of participants in each category, as appropriate. Data will be listed in data 
listings.  
Details of the statistical analyses, methods, and data conventions are described in the statistical analysis plan  (SAP) . 
All statistical tests will be 2 -sided and performed using a 0.05 significance level, leading to 
95% (2- sided) CIs.  
A closed 2 -step ordered testing procedure will be used to control overall type I error for the 
primary efficacy endpoint, central corne al ECD at Week 12. In step 1, the K-321 0.4% QID 
group will be statistically compared with the placebo group. If the step  1 comparison is 
significant, step 2 will be performed to statistically compare K-321 0.4% BID group with the placebo group. If the sta tistical comparison made during step 1 is not significant, testing will 
still be performed to compare the BID group to placebo; however, all p values will be considered nominal/descriptive only. 
No other measures will be taken to control error for the multiple secondary and exploratory 
endpoints or multiple treatment comparisons.  
7.7.[ADDRESS_1269652] and will be bas ed on assessments performed by [CONTACT_239795]. Testing will be performed in a pairwise manner with each dosing regimen (QID 
and BID) of K-321 0.4% compared to placebo. For each dosing regimen, the following 
2-sided hypothesis will be tested   
Ho: Δ = 0 versus Ha: Δ ≠ 0 
where Δ is the shift in location in central corneal ECDs  between the active and placebo 
groups being compared: ie ,  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269653] 2019 
 Page 58 Xi = e i for i = 1 to n for the placebo patients  
Yj = e j + Δ for j = 1 to m for the K-321 patients  
The Hodges- Lehmann estimate ( Hodges and Lehmann 1963) for the shift in location ( eg, the 
median of al
l differences d=Y j – X i) and Moses 95% CI ( Moses 1965) will also be presented.  
Week 12 assessments that are unable to be performed due to corneal oedema will be  
 
 
 
Week 12 assessments that are  due to patient withdrawal or missed visit will be 
 Patients who receive a 
rescue keratoplasty performed prior to Week 12 will be  
 
 
 
 
  
Sensitivity analyses will be performed by [CONTACT_904537]. The primary analysis methods will also be repeated for the FAS using 
 
 Additionally, analyses will be performed using assessments performed by 
[CONTACT_904538].  
7.7.2 Analysis of Secondary Efficacy Endpoints  
Secondary endpoints will be summar ised fo r the FAS. Central ECD which cannot be 
performed due to corneal oedema will be  for analysis. Assessments of central 
ECD, central corneal thickness, and epi[INVESTIGATOR_904498], secondary eff icacy analyses will be  
Endpoints based on continuous measures (central ECD at each visit, central corneal thickness 
change from baseline to each visit, and percent change of central corneal thickness from 
baseline to each visit) will be analy sed by [CONTACT_904539], Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269654] 2019 
 Page 59 active K- 321 0.4% treatment. The Hodges -Lehmann estimate and Moses 95% CI for the shift 
in location will also be presented  regimen to placebo.  
Endpoints based on the number and percentage of patients achieving the endpoint (patients 
wh
o achieve central ECD of 700 ce
lls/mm2 or more, patients who achieve cornea clearance 
at each
 visit, patients who achieve a cornea thickness less than or equal to baseline cornea 
thickness at each visit, and patients who have no corneal oedema at each visit) will be 
analysed by [CONTACT_540633]’s Exact or Pearson chi-square tests comparing each active K-321 
0.4% treatment regimen to placebo. The 95% CI for the difference in percentage of patients achieving the end point will also be presented.  
Endpoints based on time- to-event endpoints (time to achieve central ECD 700 ce
lls/mm2 or 
mor
e, time to cornea clearance, time to return of cornea thickness to less than or equal to 
baseline cornea thickness, time to no corneal oedema) will be analys ed by [CONTACT_904540] -rank 
tests comparing each active K-321 0.4% treatment regimen to placebo. Kaplan- Meier 
estimates and plots will also be presented. Patients who complete follow-up or discontinue 
the study without achieving the specified endpoint will be  
 Patients who receive rescue keratoplasty will be  
  
7.7.3 Analyses of Exploratory Efficacy Endpoints  
Exploratory endpoints will be summar ised for the FAS. Assessments after rescue keratoplasty 
will be  Endpoints will be analysed in a similar manner to the secondary 
efficacy endpo ints.  
Endpoints based on continuous measures will be analysed by [CONTACT_904541] K-321 0.4% treatment regimen to placebo with the 
Hodges- Lehmann estimate for the different in medians and Moses 95% CI for the difference 
in medians also presented. 
Endpoints based on the number and percentage of patients achieving the endpoint will be 
analysed by [CONTACT_904542]- square tests comparing each active K- 321 0.4% treatment 
regimen to placebo with the 95% CI for the differ ence in percentage of patients achieving the 
endpoint also presented. 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269655] 2019 
 Page 60 Endpoints based on time- to-event endpoints will be analys ed by [CONTACT_904540]- rank tests 
comparing each active K-321 0.4% treatment regimen to placebo with Kaplan- Meier 
estimates and plots also presented. Patients who complete follow-up or discontinue the study 
without achieving the specified endpoint will be  
 Patients who receive rescue keratoplasty will be  
 
7.7.4 Safety Analyses  
Safety parameters include monitoring of AEs, TEAEs, vital sign measurements, laboratory 
examinations, slit-lamp biomicroscopy, IOP, and ophthalmoscopy. 
Safety data will be summarised and listed with no statistical hypothesis testing performed. 
Continuous variables will be summar ised using the mean, the SD , median, minimum value, 
and maximum value. Categorical variables will be summar ised using frequency counts and 
percentages.  
[IP_ADDRESS]  Adverse Events  
All AEs wil l be listed and all TEAEs will be summarised. Adverse events will be deemed 
treatment- emergent if the onset date is on or after the date of first treatment. Events which are 
not treatment- emergent will be listed separately and together with all other AEs. AEs will be 
summar ised separately for the treatment period, the tapering phase, and the 9 -month 
follow-up period. Ocular TEAEs will be summarised separately from non- ocular TEAEs. 
Ocular TEAEs will be summarised separately for the study eye and non-study eye.  
Treatment -emergent AEs will be summarised by [CONTACT_1570], presenting the number and 
percentage of patients having a TEAE in each system organ class and having each individual 
TEAE based on the preferred term. Treatment -emergent AEs will also be tabulated according 
to intensity and causality. Patients who experienced multiple TEAEs for a preferred term will be counted once, similarly for patients with multiple TEAEs per system organ class.  
Deaths, SAEs, and TEAEs leading to discontinuation of study treatment will be listed 
separately and, if appropriate, summar ised by [CONTACT_1570], system organ class and 
preferred term.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269656] 2019 
 Page 61 [IP_ADDRESS]  Vital Signs 
Observed values at each visit and change from baseline values for vital sign measurements 
will be summarised descript ively by [CONTACT_1570]. All vital sign measurement data will be 
listed.  
[IP_ADDRESS]  Clinical Laboratory  
Observed values at each visit and change from baseline values for clinical laboratory evaluations will be summar ised descriptively by [CONTACT_1570]. Additionally, shift tables 
will be presented for chemistry and hematology parameters from baseline to each post-
baseline assessment. All clinical laboratory data will be listed.  
[IP_ADDRESS]  Intra-O cular  Pressure  
All IOP data will be  listed. Observed values at each visit and change from baseline values for 
IOP evaluations will be summarised descriptively by [CONTACT_904543]-study eye.  
[IP_ADDRESS]  Slit-Lamp Biomicroscopy and Ophthalmoscopy  
Ocular findings will be evaluated by [CONTACT_4868]: 
• Normal  
• Abnormal (NCS)  
• Abnormal with clinical significance (CS) 
Data from all slit -lamp biomicroscopy and ophthalmoscopy  assessments will be listed. The 
number and percentage of patients with at least [ADDRESS_1269657] treatment. A patient will be counted once even if the patient experiences 
more than 1 treatment- emergent CS  abnormality.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269658] 2019 
 Page 62 7.7.5 Other Analyses  
[IP_ADDRESS]  Patient Demographics and Other Baseline Characteristics  
Descriptive statistics will be provided by [CONTACT_904544]. Relevant medical history (ocular and  non- ocular) and 
current medical conditions will be tabulated by [CONTACT_1570]. Ocular summaries will be presented for the study eye and the non -study eye. Other relevant baseline information will 
be listed and summarised as appropriate with descriptive statistics. Analyses will be based on 
the FAS.  
[IP_ADDRESS]  Treatment Exposure and Compliance  
Descriptive statistics will be provided to characterise study treatment exposure and 
compliance using the safety set. Summaries will also be provided for the FAS if it differs 
from the safety set. Duration of exposure will be calculated in days as the (date of last dose –
 date of first dose + 1). Percent compliance will be calculated as the total number of study 
drug instillations/planned number of instillations × 100. The planed number of instillations 
for Visit 3 (Day 1) will be adjusted based on the time the descemetorhexis was completed on 
Visit 2 (Day  –1) and the time all study visit assessments are completed  on Visit 3. For all 
other study visits during the treatment period, the planed number of instillations will be 
adjusted based on the time all planned study visit assessments are completed on the 
respective study visit days, as activities on these days may reduce t he number of doses that 
can be given. The details of dosing adjustment will be provided in the SAP . For all other 
study days, the number of planned instillations will be considered to be [ADDRESS_1269659] dose. Subjects will be considered compliant with study 
treatment if the calculated percent compliance is betw een 80% and 125%, inclusive. 
 
7.7.[ADDRESS_1269660] been discontinued from the study and/or treatment before this visit. Analysis of the complete study data (through Week 52) will be performed after all patients have completed 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269661] ( eg, change to sample size or early stoppi[INVESTIGATOR_007]) are planned.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269662]® (Medidata Solutions Inc, [LOCATION_001], [LOCATION_001]). 
This EDC system is validated and compliant with US Title 21 Code of Federal Regulations (CFR) Part 11. Each person involved with the study will have an individual user name [CONTACT_904546]. Thus, the system, and subsequently any 
investigative reviews, can identify coordinators, investigators, and individuals who have 
entered or modified records, as well as the time and date of any modifications. A quality review of the data will be performed by [CONTACT_904545].  
Each eCRF is presented as an electronic copy, allowing data entry by [CONTACT_6624], who can add and edit data, identify and resolve discrepancies, and view records. This system provides 
immediate direct data transfer to the database, as well as immediate detection of 
discrepancies, enabling site coordinators to resolve and manage discrepancies in a timely 
manner.  
Paper copi[INVESTIGATOR_904499]. 
This system provides site staff, monitors, and reviewe rs with access to hard copy audits, 
discrepancy reviews, and investigator comment information.  
After all data reviews and query resolutions are complete, the SAP is approved and signed, 
and any summary/analysis populations are approved, the database will be locked.  
8.[ADDRESS_1269663]  not be present unless otherwise directed.  
Investigative site personnel will enter patient data into an EDC  system. The analysis data sets 
will be a combination of these data and data from other sources (eg, laboratory data).  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269664] 2019 
 Page 65 Clinical data management will be performed in accordance with applicable  standards 
and data cleaning procedures to ensure the integrity of the data (eg, removing errors and 
inconsistencies in the data). Adverse events and medical history will be coded using the 
MedD RA terminology. Concomitant medications will be coded using the most current 
available WHO Drug Dictionary.  
After database lock, each study site will receive an electronic copy of their site -specific 
eCRF data as entered into the EDC system for the study, including full discrepancy and audit history. Additionally, an electronic copy of all the study site’s data from the study will be 
created and sent to the sponsor for storage.  will maintain a duplicate electronic copy for 
their records. In all cases, p atient initials will not be collected or transmitted to the sponsor.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269665] 
Country regulations, US f ederal regulations, and the International Council for Harmonisation 
(ICH) guidelines require tha t approval be obtained from an IRB or IEC before participation 
of human patients in research studies. Before study onset, the protocol, informed consent, 
advertisements to be used for the recruitment of study patients, and any other written 
information reg arding this study to be provided to the patient or the patient’s legal guardian 
must be approved by [CONTACT_1201]/IEC. Documentation of all IRB/IEC approvals and of the 
IRB/IEC compliance with ICH harmonised tripartite guideline E6(R2): Good Clinical 
Practice (G CP) and with applicable regulations in the countries where the study will be 
conducted will be maintained by [CONTACT_135780].  
All IRB/IEC approvals must  be signed by [CONTACT_1201]/IEC chairman or designee and must 
identify the IRB/IEC name [CONTACT_3816], the clinical protocol by [CONTACT_21759], and the date approval or a favourable opi[INVESTIGATOR_11744]. 
The investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or otherwise specified by [CONTACT_1201]/IEC. The 
investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where 
applicable, the institution, with written reports on any changes significantly affecting the 
conduct of the study or increasing the risk to patients. 
9.[ADDRESS_1269666] their origin in 
the Declaration of Helsinki, ICH GCP, the protocol, and all applicable country and local 
regulations. 
9.3 Patient Information and Consent 
A written informed consent in compliance with regulatory authority regulations or US Title 21 CFR Part 50 shall be obtained from each patient before entering the study or 
performing any unusual or  non-routine procedure that involves risk to the patient. An 
informed consent template may be provided by [CONTACT_160527]. If any 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269667]  be reviewed by [CONTACT_134354]/IEC 
submission. Once reviewed, the consent will be submitted by [CONTACT_209806]/IEC for review and approval before the start of the study. If the ICF is revised during the 
course of the study, all active participating patients must sign the revised form.  
Before recruitment and enrollment, each prospective patient or his or her legal guardian will be given a full explanation of the study and be allowed to read the approved ICF. Once the 
investigator is assured that the patient/legal guardian understands th e implications of 
participating in the study, the patient/legal guardian will be asked to give consent to participate in the study by [CONTACT_12568]. The investigator will then sign the consent signed 
by [CONTACT_102]/legal guardian. 
The investigator shall retain the signed original ICF(s) and give a copy of the signed original 
form to the patient or legal guardian.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269668] 2019 
 Page 68 10 Investigator’s Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be patient to change based on industry and government standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the 
IRB/IEC but will not result in protocol amendments.  
10.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain patient confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission of the patient (or the patient’s legal guardian), except as necessary for monitoring 
and auditing by [CONTACT_456], its designee, the US Food and Drug Administration (FDA), the 
Medicines and Healthcare P roducts Regulatory Agency ( MHRA), other agencies, or the 
IRB/IEC.  
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties.  
10.[ADDRESS_1269669] ed during the screening process. In addition, in the 
absence of specific arrangements, neither the sponsor nor  is financially responsible for further treatment of the patient’s disease.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269670] 2019 
 Page 69 10.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R2) 8.2 
and Title 21 of the CFR by [CONTACT_44074], including but not 
limited to:  
• IRB/IEC approval. 
• Original investigator -signed investigator agreement page of the protocol. 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA  1572. 
• Curriculum vitae (CV) for the investigator and each sub -investigator listed on Form 
FDA  1572. 
• Financial disclosure information to allow the sponsor to submit complete and accu rate 
certification or disclosure statements required under [ADDRESS_1269671] provide to the sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 
1 year after the completion of the study. 
• IRB/IEC -approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to 
the patient or legal guardian, and 
• Laboratory certifications and normal ranges for any local laboratories used by [CONTACT_779], in accordance with [ADDRESS_1269672] 
The investigator agrees that the study will be conducted according to the principles of ICH E6(R2). The investigator will c onduct all aspects of this study in accordance with all 
applicable national, state, and local laws or regulations. Study information from this protocol will be posted on publicly available clinical trial registers before enrollment of patients 
begins. 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269673] the study as outlined in this protocol in accordance with 
ICH E6(R2) and all applicable guidelines, regulations , and laws , and consistent with the 
principles of the Declaration of Helsinki. 
10.[ADDRESS_1269674] research organization  and/or IRB/IEC according to the time line and method 
outlined in the protocol. In addition, the investigator agrees to submit annual reports to the 
study site IRB/IEC as appropriate.  
10.7 Investigator’s Final Report  
Upon completion of the study, the investigator, when applicable, must  inform the institution . 
Also,  the investigator/institution must  provide the IRB/IEC with a summary of the study’s 
outcome and provide the sponsor and regulatory authority(ies) with any reports required. 
10.[ADDRESS_1269675] be retained 
for a longer period, however, if required by [CONTACT_70469]. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained. The 
patients’ medical records, however, need only be retained as long as required by [CONTACT_230991], in accordance with national law.  
10.9 Publications 
After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be s ubmitted, and other related issues. The sponsor has final approval authority over all 
such issues.  

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269676] 2019 
 Page 71 Data are the property of the sponsor and cannot be published without prior authoris ation from 
the sponsor, but data and publication thereof will not be unduly withheld. 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269677] operating procedures. 
11.1.3  Inspection of Records 
Investigators and institutions involved in the study will permit study-related monitoring, 
audits, IRB/IEC review, an d regulatory inspections by [CONTACT_21766]. In the event of an audit, the investigator agrees to allow the sponsor, representatives of the sponsor, or a regulatory agency (eg, FDA or other regulatory agency) access to all 
study records.  
The investigator must  promptly notify the sponsor and  of any audits scheduled by [CONTACT_513365][INVESTIGATOR_21688]. 
11.[ADDRESS_1269678] be submitted in writing to 
the investigator’s IRB/IEC for approval before patients can be enrolled into an amended protocol or before the amendment can be implemented for patients already participating in 
the study. 

Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269679] document and explain in the patient’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
patients without prior I RB/IEC approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments must  be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, and 
to the regulatory authorities, if required.  
A deviation from the protocol is an unintended or unanticipated departure from the procedures or processes approved by [CONTACT_135785]/IEC and agreed to by [CONTACT_1275]. A significant deviation occurs when t here is non-adherence to the protocol by 
[CONTACT_710769] a significant, additional risk to the patient or to the integrity of the study. Significant deviations can include non-adherence to inclusion or 
exclusion criteria, or non -adherence to FDA regulations or ICH GCP guidelines, and will 
lead either to the patient being discontinued from study drug treatment or withdrawn from the study ( Section 4.2).  
Protocol deviations will be documented by [CONTACT_135786]. Principal investigators will be notified in writing by [CONTACT_21769]. The IRB/IEC must  be notified of all protocol deviations in a timely manner. 
11.[ADDRESS_1269680] 
visit.  
11.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the clinical study reports are prepared and provided to the regulatory agency(ies) as required by 
[CONTACT_8146](s). The sponsor will also ensure that the clinical study 
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269681] 2019 
 Page 75 reports in marketing applications meet the standards of the ICH harmonised triparti te 
guideline E3: Structure and content of clinical study reports  and the standards of regulatory 
agencies to which the clinical study reports will be submitted.  
Where required by [CONTACT_25435], an investigator signatory will be 
identi fied for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results. 
Upon completion of the clinical study report, the sponsor will provide the investigator with 
the full summary of the study results. The investigator is encouraged to share the summary 
results with the study patients, as appropriate. The study results will be posted on publicly 
available clinical trial registers.  
Kowa Research Institute, Inc.  K-321 
Protocol: K- 321-201, version 1.0 (Original)  [ADDRESS_1269682]  
Elhalis H, Azizi B, Jurkunas. UV . Fuchs endothelial corneal dystrophy. Ocul Surf. 
2010;8(4):173-84.  
Garcerant D, Hirnschall N, Toalster N, et al. Descemet's strippi[INVESTIGATOR_904500]. Curr Opin Op hthalmol. 2019;30(4):275-85. 
Hodges JL Jr, Lehmann EL. Estimates of location based on rank test. Ann. Math Statist. 1963;34(2):598-611. 
Ianchulev T, Lane S, Masis M, et al . Corneal endothelial cell density and morphology after 
phacoemulsification in patien ts with primary open -angle glaucoma and cataracts: 2 -year 
results of a randomised multicenter trial. Cornea. 2019;38(3):325-31. Jullienne R, Manoli P, Tiffet T, et al. Corneal endothelium self- healing mathematical model 
after inadvertent descemetorhexis. J Cataract Refract Surg. 2015;41(10):2313–8. Kowa Company Ltd. Ripasudil hydrochloride hydrate ophthalmic solution. Investigator’s 
Brochure, version 00.01. Tokyo ( Japan ); 2019. 115 p.  
Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25- item Nat ional Eye 
Institute Visual Function Questionnaire . Arch Ophthalmol. 2001;119(7):1050-8.  
Macsai MS, Shiloach M. Use of topi[INVESTIGATOR_904501]. Cornea. 2019;38(5):529-34.  
Moloney G, Petsoglou C, Ball M, et al. Descemetorhexis without grafting for Fuchs 
endothelial dystrophy-supplementation with topi[INVESTIGATOR_904502]. Cornea. 2017;36(6):642-8. 
Moses LE. Query  10: Confidence limits from rank tests. Technometr ics. 1965;7(2) :257-60. 
Van den Bogerd B, Dhubhghaill SN, Koppen C, et al. A review of the evidence for in vivo 
corneal endothelial regeneration. Surv Ophthalmol. 2018;63(2):149–65. 
Watanabe S, Oie Y , Fujimoto H, et al. Relationship between corneal guttae and quality of 
vision in patient s with mild Fuchs’ endothelial corneal dystrophy. Ophthalmology. 
2015;122(10):2103–9. 